Lupin Limited has informed the Exchange regarding a press release dated February 04, 2026, titled "Lupin Launches Topiramate Extended-Release Capsules in the United States ".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin Limited has announced the launch of Topiramate Extended-Release Capsules in the United States market, as per a press release dated February 04, 2026. Topiramate ER is commonly prescribed for epilepsy and migraine prevention, and this launch expands Lupin's portfolio of generic products in the US. The US is Lupin's largest international market, and adding new generic offerings typically supports revenue growth in that segment. The specific dosage strengths, market size, and competitive landscape were not detailed in the filing.
This product launch strengthens Lupin's US generics business, which is a key growth driver for the company, and is likely to be viewed positively by investors as it signals continued expansion in a high-value market.